Patent Application
20240182907
The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a RNA expression cassette, preferably a shRNA cassette, in which the expression of the RNA is controlled by the Pol III H-1 promoter. The present invention also provides cells or organisms comprising said parvovirus.
RNA interference (RNAi) was first recognized in Caenorhabditis elegans by Andrew Fire and Craig Mello, who later were awarded with the Nobel prize in 1998 for their discovery. The mechanism of RNAi is based on the sequence-specific degradation of host mRNAs by means of double-stranded RNAs complementary to the target sequence. RNAi is a naturally occurring cellular process that controls gene expression and therefore plays a pivotal role in many cellular processes, including development [1]. It is also a vital component of the immune response defending the cells against pathogens like viruses and transposons [2]. Soon after its discovery, RNAi technology was harnessed to address biological questions and treatment options for diseases owing its highly specificity and capacity to achieve potent knock-down of known genetic sequences [3]. Therapeutically, RNAi works via delivery of small RNA duplexes, including microRNA (miRNA) mimics, small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs) and Dicer substrate RNAs (dsiRNAs) [4]. All the four classes of RNAi effectors are presently tested in a number of phase I-III clinical trials against various diseases including multiple types of cancer [5]. In particular, RNA interference (RNAi) is the process where the RNA silences the gene expression. It is initiated by the enzyme Dicer, which cleaves the double stranded RNA into smaller fragments. The passenger strand is further fragmented, and the guide strand is loaded on to RNA-induced Silencing Complex (RISC). The guide strand pairs with the target mRNA and Argonaute-2, a protein, which serves as the catalytic component of the RISC, cleaves the mRNA. Typically, a short-hairpin RNA (shRNA) is added through a plasmid. The shRNA undergoes nuclear processing and is exported in the cytoplasm where shRNA is processed into a short-interfering RNA (siRNA) along with the Dicer substrate RNA (dsiRNA). The shRNA binds to a specific sequence in the mRNA via RISC. This results in the degradation of mRNA.
The most common problem that RNAi encounter is the efficient delivery of the shRNA into the cells. There are several commercially available transfection reagents for effective delivery of shRNAs, however, certain types of cells are still difficult to transfect efficiently. Examples of viruses employed for the delivery and expression of shRNAs in cancer gene therapy are adenoviruses, adeno associated viruses, lentiviruses and retroviruses. Most of these viruses however are defective in replication and therefore the silencing effect is restricted to the primary infected cells. Due to safety concerns, the use of lentiviral vectors has been limited to the in vitro and cannot be taken further to the in vivo setting.
Examples of genes targeted by RNAi-mediated anticancer therapy are KRAS, Polo-like kinase 1, Furin, Ephrin type-A receptor and c-myc. Most of the clinical studies involve siRNAs conjugated to nanoparticles (e.g. lipid nanoparticles) which have superior stability in comparison to naked siRNAs. However despite significant improvements, a rapid decline of the siRNA is observed within the first 72 h post-injection with most of the siRNA taken up by hepatocytes (approximately 50% of the injected dose is found in the liver already after 30 min from injection). Thus, efficient delivery of siRNAs remains the major bottleneck in this field [5]. As most delivery systems are transient and intracellular concentration of the siRNAs is diluted during cell division, repeated administration of the siRNAs is often required.
Short hairpin RNAs (shRNAs) are another class of RNAi effectors [6]. shRNAs typically consist of two complementary (sense and antisense) 19-29 base pairs sequences separated by a short loop of 4-11 impaired nucleotides. Typically, expression is controlled by a RNA polymerase (Pol) III promoter (e.g U6, H1) or modified pol II promoters. After transcription of the shRNA, sense and antisense strand, connected by the loop, pair together forming the characteristic hairpin structure. This structure resembles the pre-miRNA that are naturally used by the cell to regulate gene expression and requires nuclear processing [3]. After the discovery of promoter-driven expression of shRNAs, the design of viral RNAi vectors became possible [7]. Examples of viruses employed for the delivery and expression of shRNAs in cancer gene therapy are adenoviruses, adeno-associated viruses, lentiviruses and retroviruses. Most of these viruses, however, are defective in replication and therefore the silencing effect is restricted to the primary infected cells.
Oncolytic viruses (OVs) are viruses which selectively replicate in and kill cancer cells and have the ability to spread throughout the tumour while sparing normal tissues. Their anticancer potential has been demonstrated at the preclinical level against a vast variety of tumour models and a number of OVs are presently under phase I-III clinical evaluation. In particular, Talimogene laherparepvec (T-Vec; Amgen), a modified herpes simplex virus (HSV) expressing the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), has been approved recently by FDA and EMA for the treatment of unresectable metastatic melanoma. However, the promising results obtained with OVs at the preclinical levels have not always been reproduced in clinic. Tumours are often highly heterogeneous in nature and it may be that certain tumours are moderately susceptible to virus-induced oncolysis. It is also possible that within a certain tumour a fraction of cells survives virus treatment leading to tumour re-growth. The application of RNAi technology in the context of OV-based therapy is therefore very attractive because it may represent a means to reinforce the efficacy of OVs by providing the virus a additional mode of action for killing those cancer cells that are poorly sensitive to its infection. In addition, OV-mediated delivery of RNAi effectors may overcome the general hurdle of RNAi technology how to achieve high-level expression of these molecules specifically in cancer cells, in particular after intravenous administration. Furthermore, OV can replicate and spread through the tumour thereby having the potential to amplify shRNA production and delivery. Arming OVs with RNAi effectors has proven to be a valid approach in the case of oncolytic adenoviruses (Ad) e.g. Ad expressing shRNAs targeting a number of tumour related genes including VEGF, MYCN, SATB1, C-Met, Ki67, IL-8, hTERT and FAK have superior anticancer activity than their parental viruses [8-15]. It was also shown that oncolytic HSV can be engineered to efficiently express RNAi effectors (shRNAs and artificial miRNAs) [16].
There exists already a first-generation ΔH-1PVsilencer platform (WO 2013/110464 A1) that consists of a ΔH-1PV virus genome that features an in-frame deletion encompassing nucleotides (nt) 2022-2135. The left (LP) and right palindromic sequence (RP) serve as self-priming origins of replication; P4 promoter regulates the expression of the NS gene, encoding the nonstructural proteins NS1 and NS2, and P38 promoter regulates the expression of the VP gene encoding the VP1 and VP2 viral proteins. The non-coding region (NCR) is downstream the VP region and a target-specific nucleic acid cassette is inserted into the non-coding region at nucleotide 4687 of the wild-type H-1PV genome. However, it has been found out that the target-specific nucleic acid cassette inserted at the HpaI site (positions 4686-4691) is not stably maintained and compromises the fitness of the virus.
In addition, a recombinant parvovirus, which contains the shRNA CDK9 expression cassette within the 3′ end untranslated region of the virus genome at position 4570 is described in EP 3 327 124 A1 (WO 2018/096148 A1). Although the virus is efficient in gene silencing and maintains its ability to replicate, the shRNA expression cassette is gradually lost during the propagation of the virus in the NB324K production cell line.
As mentioned above, if shRNA is delivered by adenoviruses, adeno-associated viruses, lentiviruses and retroviruses, the viruses are often defective in replication and therefore the silencing effect is restricted to the primary infected cells.
Therefore, it is the object of the present invention to provide means for efficiently down-regulating the expression of cancer-related genes in a cell or organism in a more stable way.
According to the invention this is achieved by providing the subject matters defined in the claims. Preferred embodiments are mentioned in the dependent claims.
The present invention concerns a deletion variant of autonomous parvovirus H-1 expressing a RNAi effector, preferably shRNAs, targeting cancer-related genes or oncogenes, e.g. PD-L1.
H-1 PV have attracted high attention for their anti-cancer potential because they are non-pathogenic for humans and possess oncolytic and oncosuppressive properties. Pre-existing anti-viral immunity is usually not a problem for these viruses as humans are normally not exposed to rodent parvovirus infection. The parvovirus genome consists of a single stranded DNA of approximately 5100 bases containing two promoters, P4 and P38 which regulate the expression of the non-structural (NS1 and NS2) and capsid (VP1 and VP2) proteins, respectively. Activation of the P4 promoter is a critical step in the PV life cycle. The activity of the P4 promoter is later modulated by its own gene product NS1, but its initial activation is completely dependent on host cellular factors, which are mainly expressed during the S phase of the cell cycle. This dependency, together with the fact that the virus is unable to stimulate quiescent cells to proliferate, contributes to the oncotropism of the virus, which replicates preferentially in proliferating, transformed or malignant cells. In addition, parvovirus cytotoxicity is also stimulated by cellular changes associated with neoplastic transformation. NS1 is the major viral toxic protein. H-1PV has been shown to activate several death pathways in cancer cells. Although the anticancer potential of PVs is supported by a large set of preclinical studies, efficacy can be expected to be a limiting factor in clinical applications. It is possible that some cancer cells are resistant to virus treatment, causing tumour relapse.
During the experiments resulting in the present invention it could be shown that the insertion of a shRNA expression cassette at a particular site of the parvovirus genome is compatible with parvovirus packaging capacity, does not interfere with viral replication and enhances the intrinsic cytotoxicity of the virus. The virus expresses high levels of shRNAs and is very efficient in gene silencing. The big advantage of H-1PV-silencer in comparison with replication defective vectors resides in its capacity to replicate and propagate in proliferating cells, e.g., cancer cells. Every infected/transduced cell theoretically could become a producer of novel viral particles. Progeny virions of through second rounds of infection could spread through the tumour and efficiently delivery and express therapeutic shRNAs. In this setting, the silencing signal could be amplified beyond the initial inoculum. Together, parvovirus-based vectors and shRNA technology compensate each other limitations: the natural oncotropism of parvovirus should specifically and effectively deliver to and mediate transduction of the shRNAs in proliferating cells, e.g., cancer cells.
The viral genome (top) is shown as a single line terminating in disparate hairpin telomeres which serve as self-priming origins of replication. The hairpins, drawn to represent their predicted structures, are scaled approximately 20×relative to the rest of the genome. The viral early P4 and late P38 promoters regulate the expression of the transcription units encoding the non-structural NS1 (arrowed light grey box) and capsid VP (arrowed dark grey box) proteins respectively. Transcriptional promoters are indicated by solid arrows. The grey triangle indicates the position of an in frame 114-nucleotide internal deletion. The non-coding region is downstream the VP region and it is supposed to be involved in the regulation of viral replication. The shRNA cassette (bottom), including H1 Pol III promoter and shRNA sequence, is inserted at nt 4480 within viral genome.
Virus production plan was adopted for checking the stability of the shRNA expression cassette via consecutive infection rounds as described in methods.
B) Evaluation of Stability of the shRNA Expression Cassette at Nt4480
The viruses either ΔH-1PVshEGFP, ΔH-1PVshPD-L1_1 or ΔH-1PVshPD-L1_2, obtained from each passage P2, P3, P4 and P5 with procedures as shown in (A). The virus DNA was extracted and the genomic fragment including the shRNA cassette was amplified by PCR using primers flanking the cassette. The PCR product of AH-1PV was loaded as control.
Titration of viruses were performed by plaque assay (light grey). Results are given from the representatives of the two independent experiments. Real-time PCR was conducted for quantification of the encapsidated viral genomes (dark grey). Results are presented with average of the two independent experiments.
U251 cells were infected with increased amount of MOI (PFU/cell) of the indicated viruses and grown for 72 h before to be lysed. Total cell extracts were subjected to SDS-PAGE followed by immunoblot analysis of the protein levels of Flag tagged PD-L1, NS1 and Vinculin (loading control) using specific antibodies.
(B) qRT-PCR
U251 cells were infected as described in (A). Cells were harvested at 72 h post-infection and total RNA isolated and reverse transcribed. PD-L1 mRNA levels were quantified by qRT-PCR using specific primers. The expression levels of PD-L1 gene were normalized with housekeeping gene IRNA 18S. Values are expressed as relative to values obtained in mock-treated cells.
AsPC-1 cells were infected with increased amount of MOI (PFU/cell) of the indicated viruses and grown for 72 h before to be lysed. Western blot was performed as described in
(B) qRT-PCR
AsPC-1 cells were infected as the same as in (A). RT-PCR was carried out as described in
Either AsPC-1 (left panel) or U251 (right panel) cells were first transfected with TCR activator alone or TCR activator/PD-L1, and followed by infection with ΔH-1PVshPD-L1 as well as ΔH-1PVshEGFP as indicated MOI (PFU/cell). The infected cells were pre-incubated with either anti-PD-L1 neutralizing (NAb) or control antibodies (CAb) as illustrated amount (ng/ml) and followed by co-culture with Jurkat cells. The NFAT-luciferase reporter activity was measured by ONE-Step luciferase assay. Relative ratio of luminescence under different treatments was calculated as described in methods.
As PC-1 cells real time proliferation by Incucyte® single spheroid assay was documented upon infection of ΔH-1PVshEGFP or ΔH-1PVshPD-L1 at a MOI 5 PFU per cell. Cells treated with an equal volume of vehicle were used as control.
Parvovirus H-1, complete genome (SEQ ID NO: 12) GenBank: X01457.1
Thus, the present invention provides a parvovirus based on a parvovirus H-1 deletion variant for down regulating the expression of a target gene in a cell characterized in that the parvovirus H-1 deletion variant contains a deletion encompassing the nucleotides 2022-2135, wherein the target specific nucleic acid is inserted in an untranslated region downstream of the H-1 parvovirus VP gene and is expressible under the control of a promoter or promoter region recognizable by an RNA polymerase in the cell, wherein said target specific nucleic acid is transcribable in an RNAi, and wherein said parvovirus is capable of replicating and propagating in the cell.
The parvovirus H-1 deletion variant (ΔH-1PV) features an in-frame deletion encompassing nucleotides (nt) 2022-2135 of wildtype parvovirus H-1 (
The target specific nucleic acid is inserted into the viral genome in such a way that viral replication and cytotoxicity are not affected, i.e. downstream of the parvovirus VP gene encoding the capsid proteins of the parvovirus. Preferably, the target specific nucleic acid cassette is inserted at nucleotide 4480 of the ΔH-1PV genome. The inventors have conducted several tests to determine the most suitable insertion site. When the shRNA expression cassette was inserted at positions 4815 or 4465, the shRNA cassette was lost in passage 1 or 2. Inserting the shRNA expression cassette at positions 4598 or 4469 improves the stability of the cassette maintenance, i.e. it remains stably integrated into the viral genome in passage 3. This is even better than the insertion into the HpaI restriction enzyme site used in n the first generation ΔH-1PVsilencer platform (WO 2013/110464 A1). Best results were achieved when the shRNA expression cassette was inserted at position 4480. It is stably integrated into the viral genome in passage 4 with greater virus production as well as infectivity. The inventors could present a proof of concept that the novel cassette insert site at position 4480 is universal for any shRNAs.
In a preferred embodiment the target gene is PD-L1. PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1) play a key role in negative regulation of T cell-mediated immune responses and serves as a mechanism for tumors to evade antigen-specific T cell immune responses. Thus, the blockade of PD-1 or PD-L1 is a suitable way for tumor treatment. Multiple additional immune-checkpoint receptors and ligands, some of which are selectively upregulated in various types of tumor cells, are prime targets for blockade, particularly in combination with approaches that enhance the activation of antitumor immune responses, such as vaccines. Presently, the blockade is achieved through the administration of anti-PD1 or anti-PD-L1 antibodies. Anti-PD-L1 antibodies and methods of making the same are known in the art. Such antibodies to PD-L1 may be polyclonal or monoclonal, and/or recombinant, and/or humanized. Examples of antibodies to PD-L1 are disclosed in U.S. Pat. No. 8,217,149, U.S. application Ser. No. 13/511,538, US Application Ser. No. 13/478,511. Currently three antibodies against PD-L1, namely, atezolizumab, avelumab and durvalumab were approved by FDA. However, there are still unsolved problems associated with the administration of currently known checkpoint inhibitors:
(1) Adverse immune effects: the drawback of releasing the immune brake is the induction of toxicity in healthy tissues in the patients treated with immune checkpoint inhibitors (ICIs). The patients develop immune-related adverse events (irAEs), which are a unique spectrum of side effects of ICIs that resemble autoimmune responses. irAEs affect almost every organ of the body and are most commonly observed in the skin, gastrointestinal tract, lung, and endocrine, musculoskeletal and other systems. ICIs have significant clinical anticancer efficacy but often severe systemic toxicity. Thus, the incidence of irAEs of up to 50% has prevented their widespread and universal use.
(2) Mutation of the target protein PD-L1 results in treatment resistance
(3) for example, pancreatic ductal adenocarcinoma (PDAC) has demonstrated disappointing results in trials of single-agent immune checkpoint blockades. The possible reason for the failure may be due to the combination of immune escape mechanisms and low mutation burden in PDAC.
Therefore, it calls for new strategies for PD-L1 blockade as an anticancer therapeutic target gene since PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. In addition, it boosts cancer cell growth and promotes tumorgenesis.
In particular, the inventors generated the pΔH-1PVshPD-L1 and pΔH-1PVshEGFP infectious molecular clones by inserting shRNA expression cassettes within non-coding region of viral genome (
To select the most efficient shRNA sequences targeting PD-L1, the inventors developed the stable cell lines overexpressing Flag-tagged PD-L1 either in pancreatic ductal adenocarcinoma (PDAC) AsPC-1 or glioblastoma multiforme (GBM) U251 cells to evaluate the silencing efficiency upon infection with AH-1PVshPD-L1 bearing different shRNA sequences against PD-L1 gene. As a result, the inventors chose ΔH-1PVshPD-L1_1 with more potent in PD-L1 gene silencing according to the evaluation of knocking down efficacy for further analysis. Unless otherwise stated, the term ‘ΔH-1PVshPD-L1 1’ refers hereafter to ΔH-1PVshPD-L1. AsPC-1 1 or U251 cells overexpressing Flag-tagged PD-L1 were infected with increasing amounts (
The binding of programmed cell death protein 1 (PD-1), a receptor expressed on activated T cells, to its ligands, PD-L1 on most cancers, negatively regulates immune responses. The PD-1/PD-L1 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance [35]. To explore the possibility that inhibition of PD-1/PD-L1 interaction could be achieved by silencing PD-L1 gene, the inventors tested if ΔH-1PVshPD-L1 can disrupt PD-1/PD-L1 interaction in a bioluminescent cell-based assay. Either AsPC-1 or U251 cells overexpressed PD-L1 and TCR activator were treated with anti-PD-L1 neutralizing antibodies as well as control antibodies, or infected with either ΔH-1PVshPD-L1 or ΔH-1PVshEGFP at a MOI (pfu/cell) of 12 (AsPC-1) and 2 (U251) as illustrated in
This innovative virus represents generation of parvovirus which not only has the characteristics of the original H-1PV, but also has the competitive advantage with significant functions of gene silencing that other products do not show. The following results are a preclinical proof-of-concept that the ΔH-1PV pSilencer expressing shRNAs against the PD-L1 gene have a unique, superior anticancer profile through:
The term “PD-L1 specific nucleic acid” as used herein refers to a nucleic acid comprising at least 15, 20, 25, 50, 100 or 200 consecutive nt having at least about 75%, particularly at least about 80%, more particularly at least about 85%, quite particularly about 90%, especially about 95% sequence identity with the complement of a transcribed nucleotide sequence of the PD-L1 target gene. The PD-L1 sequence is known and, for example, described in publications like Breton et al. [32], Wang et al. and Jeffrey et al. [33]. Preferably, the following sequence was used for downregulation: 5′GATATTTGCTGTCTTTATA-3′ (SEQ ID NO:1). With a RNA matching this sequence it was possible to target all known isoforms of PD-L1 (GenBank Accession No. NM 014143).
In the present invention the PD-L1 gene can be down regulated in an in vivo cell or an in vitro cell (ex vivo). The cell may be a primary cell or a cell that has been cultured for a period of time or the cells may be comprised of a cultured cell line. The cell may be a diseased cell, such a cancer cell or tumor or a cell infected by a virus. The cell may be a stem cell which gives rise to progenitor cells, more mature, and fully mature cells of all the hematopoietic cell lineages, a progenitor cell which gives rise to mature cells of all the hematopoietic cell lineages, a committed progenitor cell which gives rise to a specific hematopoietic lineage, a T lymphocyte progenitor cell, an immature T lymphocyte, a mature T lymphocyte, a myeloid progenitor cell, or a monocyte/macrophage cell. The cell may be a stem cell or embryonic stem cell that is omnipotent or totipotent. The cell may be a nerve cell, neural cell, epithelial cell, muscle cell, cardiac cell, liver cell, kidney cell, stem cell, embryonic or foetal stem cell or fertilised egg cell.
Preferably, said parvovirus variant is formulated as a pharmaceutical composition, wherein the parvovirus is present in an effective dose and combined with a pharmaceutically acceptable carrier.
“Pharmaceutically acceptable” is meant to encompass any carrier which does not interfere with the effectiveness of the biological activity of the active ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Additional pharmaceutically compatible carriers can include gels, bioadsorbable matrix materials, implantation elements containing the parvovirus (therapeutic agent), or any other suitable vehicle, delivery or dispensing means or material (s). Such carriers can be formulated by conventional methods and can be administered to the subject at an effective dose.
An “effective dose” refers to amounts of the active ingredients that are sufficient to effect treatment. An “effective dose” may be determined using methods known to one skilled in the art (see for example, Fingl et al., The Pharmocological Basis of Therapeutics, Goodman and Gilman, eds. Macmillan Publishing Co., New York, pp. 1-46 ((1975)).
Administration of the parvovirus may be effected by different ways, e.g. by intravenous, intratumoral, intraperitoneal, topical or intradermal subcutaneous, intramuscular, administration. The route of administration, of course, depends on the kind of therapy. Preferred routes of administration are intravenous (i.v.), intratumoral or endobronchial administration. If infectious virus particles are used which have the capacity to penetrate through the blood-brain barrier, treatment could be performed or at least initiated by intravenous injection of, e.g., H-1PV virus.
The dosage regimen of the parvovirus is readily determinable within the skill of the art, by the attending physician based an patient data, observations and other clinical factors, including for example the patient's size, body surface area, age, sex, the particular modified parvovirus etc. to be administered, the time and route of administration, the type of mesenchymal tumor, general health of the patient, and other drug therapies to which the patient is being subjected.
As another specific administration technique, the parvovirus can be administered to the patient from a source implanted in the patient. For example, a catheter, e.g., of silicone or other biocompatible material, can be connected to a small subcutaneous reservoir (Rickham reservoir) installed in the patient, e.g., during tumor removal, or by a separate procedure, to permit the parvovirus to be injected locally at various times without further surgical intervention. The parvovirus can also be injected into a tumor by stereotactic surgical techniques or by neuronavigation targeting techniques.
Administration of the parvovirus can also be performed by continuous infusion of viral particles or fluids containing viral particles through implanted catheters at low flow rates using suitable pump systems, e.g., peristaltic infusion pumps or convection enhanced delivery (CED) pumps.
As yet another method of administration of the parvovirus is from an implanted device constructed and arranged to dispense the parvovirus to the desired tissue. For example, wafers can be employed that have been impregnated with the parvovirus, e.g., parvovirus H1, wherein the wafer is attached to the edges of the resection cavity at the conclusion of surgical tumor removal. Multiple wafers can be employed in such therapeutic intervention. Cells that actively produce the parvovirus H1 variant, can be injected into the tumor, or into the tumor cavity after tumor removal.
In a particularly preferred embodiment of the present invention, the target specific nucleic acid is inserted at position 4480 of the H-1PV genome. The underlying vector is pdB del H-1PV which is described in EP 2 397 542 A1.
In a further particularly preferred embodiment of the present invention, the promoter or promoter region recognizable by RNA polymerases is a RNA-polymerase II (Pol II) promoters such as for instance CMV, P38 and human ubiquitin C or RNA-polymerase III (Pol III) promoters such as U6, H1, 7SK and tRNA. An example of a particularly preferred RNA-polymerase III (Pol III) promoter is the RNA-polymerase III H1 promoter.
In a preferred embodiment of the present invention the PD-L1 specific nucleic acid is a shRNA. A shRNA is a small hairpin RNA or short hairpin RNA that is a sequence of RNA that makes a tight hairpin turn that can be used to silence gene expression via RNA interference. The shRNA hairpin structure is cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC). This complex binds to and cleaves mRNAs which match the siRNA that is bound to it. However, the insertion of other RNAi triggering molecules such as microRNAs and/or antisense oligonucleotides is also possible.
In a further particularly preferred embodiment of the present invention, the PD-L1 specific nucleic acid, e.g., shRNA, has a length of at least 15 nucleotides. In a particular preferred embodiment the PD-L1 sequence matches the sequence 5 ‘GATATTTGCTGTCTTTATA-3’ (SEQ ID NO:1) of PD-L1 sequence as previously described [32]. The PD-L1 gene is alternatively spliced which results in multiple transcript variants. Out of the known four variants, one is non-coding and three codes for the different isoforms of PD-L1 protein are existing.
The present invention also relates to a rodent parvovirus as characterized above for use in treating cancer.
In a preferred embodiment, said parvovirus can be used for treating a tumour, in particular (but not exclusively) prostate cancer, pancreatic carcinoma, brain cancer (preferably gliomas), cervical carcinoma, lung cancer, head and neck cancer, breast cancer or colon cancer.
In a further preferred embodiment, said parvovirus can be used for the treatment of a tumour characterized in that the cells of said tumour are resistant to chemotherapy and/or radiotherapy.
Patients treatable by the parvovirus according to the invention include humans as well as non-human animals. Examples of the latter include, without limitation, animals such as cows, sheep, pigs, horses, dogs, and cats.
The present invention also provides a cell of an animal, fungus or protist comprising a parvovirus as hereinbefore described. In an embodiment, the cell is in vitro. The cell is preferably an animal cell, an isolated human cell, an in vitro human cell, a non-human vertebrate cell, a non-human mammalian cell, fish cell, cattle cell, goat cell, pig cell, sheep cell, rodent cell, hamster cell, mouse cell, rat cell, guinea pig cell, rabbit cell, non-human primate cell, nematode cell, shellfish cell, prawn cell, crab cell, lobster cell, insect cell, fruit fly cell, Coleapteran insect cell, Dipteran insect cell, Lepidopteran insect cell or Homeopteran insect cell.
Finally, the present invention also provides a transgenic, non-human animal, fungus or protist comprising a parvovirus as hereinbefore described. Transgenic animals can be produced by the injection of the parvovirus into the pronucleus of a fertilized oocyte, by transplantation of cells, preferably undifferentiated cells into a developing embryo to produce a chimeric embryo, transplantation of a nucleus from a recombinant cell into an enucleated embryo or activated oocyte and the like. Methods for the production of transgenic animals are well established in the art and, e.g., described in US patent 4,873, 191.
In summary, the new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in frame-deletion within the NS region (ΔH-1PV) and harbouring an RNA expression cassette, preferably a shRNA expression cassette, in which the expression of the shRNA is controlled by the Pol III H1 promoter. The ΔH-1PVsilencer is effective in gene silencing while keeping its ability to replicate and be fully infectious. In the present invention the ΔH-1PVsilencer was used to silence the PD-L1 gene whose activity is known to cause an impaired functioning of the immune system. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. Transfection of the plasmids in HEK293T cells generated fully infectious viral particles that can be further amplified via infection in NB324K cells following a classical parvovirus production protocol.
The below examples explain the invention in more detail.
pΔH-1PVRNAi contains a ΔH-1PV viral genome featuring with an in-frame deletion of 114 nucleotide, from nucleotide 2022 to 2135 according to the NCBI gene bank (reference sequence X01457.1;
The AsPC-1, U251 and HEK293T cell lines were grown in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, Munich, Germany) supplemented with 10% fetal bovine serum (FBS, Gibco, Life Technologies, Darmstadt, Germany). PD-1/NFAT reporter Jurkat cells (BPS Bioscience, CA, USA) were cultured in Roswell Park Memorial Institute medium 1640 (RPMI, Invitrogen) supplemented with 10% FBS. NB324K cells were grown in Minimum Essential Medium (MEM, Sigma-Aldrich, Munich, Germany), supplemented with 5% FBS. All media contained 2 mM l-glutamine (Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). All cells were grown at 37° C., 5% CO2 atmosphere, 95% humidity and routinely checked for mycoplasma contamination using the Mycoplasma Detection Kit according to the manufacturer's instructions (Venor GeM, Minerva Biolabs, Berlin, Germany).
Generation of AsPC-1 and U251 stable cell lines was carried out by using a pS/MARt DNA Vector expressing Flag tagged PD-L1 according the methods previously described [37]. Selection of positive clones was done on a medium containing 1 μg/ml puromycin according to the manufacturer's protocol (Invitrogen, C10459). A pool of selected clones was used in this study.
Evaluation of stability of the shRNA expression cassette. Plasmids harboring the viral genome with shRNA expression cassette, were transiently transfected in HEK293T cells. After 3 days cells were harvested and viral particles released through three freeze-thaw cycles. Crude cell extracts were digested with Benzonase nuclease (Merck, Germany) and virus titers were quantified by real-time PCR and represented as encapsidated viral genomes per ml (Vg/ml) according to the methods previously described [26]. This period is defined as passage 0 stage (P0). The further amplification of the viral stocks was carried out in NB324K producer cells using a fraction of the virus produced in HEK293T cells as inoculum. Cells were harvested after 3-5 days post-infection and treated as described above and this period is namely as passage 1 (P1). The viruses were harvested from every passage as illustrated in
Cells were scraped in the culture medium, harvested and washed with PBS. Cell pellets were lysed on ice for 30 min in lysis buffer (20 mM Tris-HCl at pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% Na-deoxycholate) containing protease (Roche Diagnostics, Mannheim, and phosphatase Germany) inhibitors (Sigma-Aldrich). Cell debris was removed by centrifugation at 13,000 rpm for 15 min at 4° C. The supernatants were kept at −80° C. for further analysis. Total cell extracts (20 μg) were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a Hybond-P membrane (GE Healthcare). The following antibodies were used for analysis: mouse monoclonal anti-vinculin (sc-25336; Santa Cruz Biotechnology, Heidelberg, Germany, used at 1:10,000 dilution), polyclonal anti-NS1 SP8 antiserum (1:3,000), mouse monoclonal anti-Flag (AHP1074; AbD Serotec) at 1:2,000 dilution, rabbit anti-PD-L1 antibody at 1:1,000 dilution (PA5-20343, Thermo Fisher, USA). After incubation with horseradish peroxidase conjugated secondary antibodies (Santa Cruz Biotechnology) at 1:5,000 dilution, proteins were detected with ECL substrate solution in a Vilber Lourmat chemiluminescence detection system (Software, Chemi-Capt 5000).
Total RNA was isolated using the TRIzol® Reagent RNA-extraction kit (Invitrogen) according to the manufacturer's instructions. 1 μg total cellular RNA was digested with 1 unit DNase I (Promega) at 37° C. for 20 min to remove genomic DNA contamination, before processing for reverse transcription (RT) with oligo (dT) primers and reverse transcriptase of Moloney murine leukaemia virus (Promega). For each cDNA sample, a control was produced with an RT mixture to which no reverse transcriptase was added, in order to detect potential contamination of the cDNA sample with residual genomic DNA. Quantitative PCR using a fraction of the cDNA as a template was performed with the primer pairs in Table 1.
30 rRNA 18S was chosen as internal control as previously described [29]. The threshold cycle of fluorescence (Ct) for each sample was determined by real-time PCR using the Mastercycler® ep realplex system (Eppendorf, Hamburg, Germany). Relative quantification of gene expression between the groups was performed applying the 2-44Ct method [34]. Results are presented as fold expression compared to transcript levels of non-infected cells (mock).
AsPC-1 and GBM U251 cells were seeded in 12-well plates at a density of 4×105 and 2×105/mL. After 24 h, cultures were transfected with 1 μg of vector expressing TCR activator (BPS Bioscience, CA, USA) as well as plasmids expressing TCR activator/PD-L1 (BPS Bioscience, CA, USA) in the presence of 3 μl metafectene reagent according to manufacturer's instructions (Biontex Laboratories GmbH, Munich, Germany). After 24 h, cells were trypsinized and split in 96-well plates at a density of 4,2×104 for AsPC-1 and 2×104 for GBM U251 cell line, meanwhile keeping the transfected cell lines at number with 4×105 of cells in 6 cm dish for evaluation of PD-L1 gene expression upon treatments. The cells either in 96-well plates or 6 cm dished were incubated for 8 h after splitting and then infected (or not) with either ΔH-1PVshPD-L1 or ΔH-1PVshEGFP at a MOI (pfu/cell) of 12 (AsPC-1) and 2 (U251).
2. Co-Culture with PD-1/NFAT Reporter Jurkat Cells.
PD-1/NFAT reporter Jurkat cells were purchased from BPS Bioscience (CA, USA). Briefly, the infected cells in 96-well plates at post-infection 68 h, were pre-incubated with either anti-PD-L1 neutralizing (#71213, BPS Bioscience, CA, USA) or control antibodies (PA5-20343, Thermo Fisher, USA) at dilution 50 ng/ml in the medium according to manufacturer's instructions and incubate for 30 min at 37° C. followed by co-culture with 6×104 Jurkat cells per well for 16 h at 37° C. incubator. After incubation, the ONE-Step luciferase assay (BPS Bioscience, CA, USA) was performed by adding the luciferase reagent to treated wells as well as untreated controls for 30 min followed by luminescence measurement. The induction of NFAT luciferase reporter expression under either different treatments or controls, is calculated as average of background-subtracted luminescence. Results are presented as a relative ratio of average luminescence of TCR activator/PD-L1 expressed sample versus average luminescence of TCR activator alone expressed sample under different treatments as well as controls.
3D cell spheroids represent the heterogeneity of a tumor model because cells in the outer layer of the spheroid have access to nutrients and oxygen, whereas in the core of the spheroid a hypoxic region is formed by accumulation of degraded products of cells. Spheroids were created from 20000 AsPC-1 cells using hanging drop method in the presence of 30% methylcellulose stock solution as previously described [38]. The formed spheroids after 2-3 days were transferred to a low attachment round-bottom 96-well plates. 50 μl/well of complete medium with or without ΔH-1PVshEGFP or ΔH-1PVshPD-L1 was added. The size of spheroid was analyzed in real-time with the Incucyte® 3D single spheroid assays using the acquisition and analysis tool for spheroids. Analysis was performed with the IncuCyte® S3 2018A software.
It is known that PD-L1 is associated with tumor growth and progression. In order to evaluate the role of PD-L1 in the growth of human pancreatic carcinoma AsPc-1 cells, the down-regulation of PD-L1 on the cell proliferation in vitro was examined by using 3D spheroids. The 3D spheroids are part of a high translational relevant model featuring more relevance to tumor biology that is represented by the heterogeneity of cancer cells. The size of spheroids upon treatment with ΔH-1PVshEGFP or ΔH-1PVshPD-L1 at a MOI 5 PFU per cell was measured with Incucyte® 3D single spheroid assays using the acquisition and analysis tool for spheroids. The Incucyte® 3D product portfolio (system, software, reagents) is available from Sartorious AG, Göttingen, Germany. This device is able to monitor cell proliferation in real time. As shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 21168526.8 | Apr 2021 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/059920 | 4/13/2022 | WO |
